Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease

Table 2

The effect of ERT on bilirubin and total antioxidant status in patients with FD.

	ERT+ ()	ERT− ()	Controls ()	value
	Males + females
Bilirubin [μmol/L]	9.7 [8.6–15.5]	7.2 [5.6–8.7]		0.004
TAS	7.14 ± 1.9	6.10 ± 1.2		0.036
		6.10 ± 1.2	6.92 ± 2	0.059
	7.14 ± 1.9		6.92 ± 2	0.503
	Males
TAS	7.3 ± 2 ()	()	7.43 ± 1.9 ()	0.794
	Females
Bilirubin [μmol/L]	8.9 ± 0.8 ()	7.5 ± 1.9 ()		0.186
TAS	6.5 [5.5–7.6]	5.8 [5.2–7.4]		0.201
	6.5 [5.5–7.6]		6.0 [4.8–7.2] ()	0.235

Out of the entire group, 55% of patients were treated with ERT (enzyme replacement therapy) (95% men and 30% women). TAS, total antioxidant status, was determined according to [26]. FD: Fabry disease. Only two male FD patients were untreated with ERT, making comparison with the untreated group impossible.